Home / Stocks / Krishna Inst Of Med Sci L
KIMS

Krishna Inst Of Med Sci L Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹767.8

Change

+8.8 (1.16%)

Open

₹754.05

Prev. Close

₹759.0

Day High

₹770.0

Day Low

₹754.05

Volume Analysis

Traded

196,785

Delivered

98,450

Delivery %

50.03%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (0)

No signal for this stock

Weaknesses (1)

  • •Promoter holding is falling

Opportunities (1)

  • •Strong 3-year revenue growth (21.1%)

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹789.8 ₹779.9 ₹773.85 ₹763.95 ₹757.9 ₹748.0 ₹741.95
Fibonacci ₹779.9 ₹773.81 ₹770.04 ₹763.95 ₹757.86 ₹754.09 ₹748.0
Camarilla ₹772.19 ₹770.72 ₹769.26 ₹763.95 ₹766.34 ₹764.88 ₹763.41

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+24.62%

1 Week

+5.57%

1 Month

+13.9%

3 Months

-1.88%

6 Months

+0.48%

1 Year

+14.08%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹112.69

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

4.28%

Net margin 4.29% × asset turnover 0.44x × equity multiplier 2.27x

Company Overview

Sector

Healthcare

Market Cap

₹31,903 Cr

P/E (TTM)

157.0

ROE

11.3%

Book Value

₹93.6

Face Value

₹2.0

Source: Screener.in (Consolidated figures) — data as of 18 Nov 2026. Not investment advice.

TopFund Analysis

Krishna Inst Of Med Sci L lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 50/100. The strongest factor is Risk & Volatility (69/100), while Valuation (0/100) is the weakest area to weigh before deciding. Notably: Promoter holding is falling. Strong 3-year revenue growth (21.1%).

TopFund Score — Fundamentals Quality

50/100 — Average

Data confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

65

Growth

53

Valuation

0

Cash Flow

49

Corporate Governance

31

Momentum

65

Institutional Ownership

56

Business Quality

54

Risk & Volatility

69

Liquidity

67

From Screener.in

  • +Company is expected to give good quarter
  • +Company's median sales growth is 21.9% of last 10 years
  • −Stock is trading at 8.11 times its book value
  • −Though the company is reporting repeated profits, it is not paying out dividend
  • −Promoter holding has decreased over last 3 years: -6.20%

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

KIMS schedules Investec Pune Confluence group meeting on November 19, 2026.

KIMS to attend Avendus Spark INDX Annual Investor Conference on November 17, 2026 in Mumbai.

Audio recording of Q2 FY27 investor/analyst conference call dated November 5, 2026 posted online.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 652 606 634 688 777 772 797 872 961 998 1,075 1,180 1,344
Expenses + 475 459 475 509 559 585 599 679 757 799 868 956 1,084
Operating Profit 177 147 159 179 218 187 198 193 204 199 206 223 260
OPM % 27.0% 24.0% 25.0% 26.0% 28.0% 24.0% 25.0% 22.0% 21.0% 20.0% 19.0% 19.0% 19.0%
Other Income + 3 3 4 5 5 18 15 7 4 5 1 17 32
Interest 9 12 16 18 20 26 27 33 45 57 68 83 66
Depreciation 33 35 46 39 41 45 53 53 66 79 85 101 121
Profit before tax 139 102 100 127 162 135 134 114 97 69 55 57 106
Tax % 27.0% 25.0% 28.0% 25.0% 26.0% 31.0% 21.0% 25.0% 26.0% 24.0% 40.0% 34.0% 29.0%
Net Profit + 101 77 72 95 121 92 106 85 72 52 33 37 75
EPS in Rs 2 2 2 2 3 2 3 2 2 1 1 1 2
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 16 8 10 14 19 27 26 27 24 29 35 35 40

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 512 567 664 918 1,123 1,330 1,651 2,198 2,498 3,035 3,905 4,596
Expenses + 403 450 593 833 872 953 1,126 1,587 1,850 2,242 3,090 3,708
Operating Profit 109 118 71 85 251 377 524 611 648 793 815 889
OPM % 21.0% 21.0% 11.0% 9.0% 22.0% 28.0% 32.0% 28.0% 26.0% 26.0% 21.0% 19.0%
Other Income + 5 3 37 6 5 9 27 41 13 43 17 56
Interest 37 32 88 49 44 37 22 37 55 100 215 274
Depreciation 36 35 40 56 71 70 73 129 147 177 283 385
Profit before tax 41 53 -20 -15 141 279 457 485 460 558 334 286
Tax % 32.0% 37.0% 126.0% 223.0% 18.0% 26.0% 25.0% 25.0% 27.0% 26.0% 28.0% —
Net Profit + 28 33 -46 -49 115 205 344 366 336 415 242 197
EPS in Rs 1 1 -1 -1 3 5 8 8 8 10 6 5
Dividend Payout % 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% —
Sales growth — 11 17 38 22 18 24 33 14 21 29 35

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 193 255 -209 466 524 786 1,307 1,590 1,748 2,058 2,167 3,848
Borrowings + 256 280 753 336 369 316 257 678 1,355 2,562 4,253 3,538
Other Liabilities + 146 167 359 237 228 253 260 553 636 990 1,190 1,442
Total Liabilities 665 774 954 1,114 1,194 1,433 1,904 2,901 3,820 5,689 7,691 8,912
Fixed Assets + 515 518 755 863 916 931 1,005 1,766 2,434 3,348 5,710 6,324
CWIP 2 64 0 0 2 9 21 477 600 1,214 606 518
Investments 11 14 0 0 0 0 332 68 157 99 103 413
Other Assets + 137 177 199 250 276 493 546 590 629 1,028 1,271 1,657
Total Assets 665 774 954 1,114 1,194 1,433 1,904 2,901 3,820 5,689 7,691 8,912
Equity Capital 70 72 50 74 74 78 80 80 80 80 80 84

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 95 82 106 134 202 356 324 432 521 582 511
Cash from Investing Activity + -41 -100 -64 -110 -125 -354 -412 -416 -753 -1,116 -1,452
Cash from Financing Activity + -65 24 -39 -27 -44 10 61 20 217 543 940
Net Cash Flow -11 5 3 -3 32 12 -26 36 -15 9 -1
Free Cash Flow 61 -18 49 57 150 262 154 -140 -125 -380 -902
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 88 80 192 195 102 104 86 87 102 91 81

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 38.82% → 32.65%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 11.67% 11.32% 11.22% 13.03% 13.45% 13.78% 18.68% 18.74% 18.85% 18.82% 18.32% 19.1%
Promoters 38.82% 38.82% 38.82% 38.82% 38.82% 38.82% 34.11% 34.11% 34.11% 34.11% 32.49% 32.65%
FII 15.27% 16.73% 17.84% 15.85% 15.68% 15.44% 15.54% 15.03% 14.33% 14.57% 14.75% 15.01%
DII 34.24% 33.13% 32.12% 32.29% 32.05% 31.95% 31.65% 32.12% 32.72% 32.5% 34.42% 33.22%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Krishna Inst Of Med Sci L (this stock) 31,903 157.0 8.11 11.3%
Acutaas Chemicals Limited 32,281 73.5 17.37 24.0%
Piramal Pharma Limited 32,557 — 4.0 -3.83%
Wockhardt Limited 32,944 82.4 6.39 6.11%
Dr. Lal Path Labs Ltd. 33,582 55.5 12.2 22.3%
Rubicon Research Limited 28,511 87.8 20.12 27.0%
Neuland Lab Ltd. 27,106 59.9 13.35 21.2%

Which Mutual Funds Hold Krishna Inst Of Med Sci L?

Frequently Asked Questions about Krishna Inst Of Med Sci L

Community Sentiment

What are other investors saying about Krishna Inst Of Med Sci L?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.